Back to News
Market Impact: 0.3

LRCX Factor-Based Stock Analysis

LRCXNDAQ
Company FundamentalsCorporate EarningsAnalyst InsightsCapital Returns (Dividends / Buybacks)Technology & Innovation
LRCX Factor-Based Stock Analysis

Lam Research Corporation (LRCX), a large-cap semiconductor stock, received an 86% rating from Validea's Warren Buffett-inspired Patient Investor model. This score indicates strong fundamental alignment with the strategy's focus on long-term, predictable profitability and reasonable valuations, primarily due to factors like predictable earnings, low debt, and robust free cash flow. While LRCX passed most key fundamental tests, it notably failed on Return on Total Capital.

Analysis

Lam Research Corporation (LRCX) demonstrates strong alignment with long-term value investing principles, according to a Validea report based on Warren Buffett's 'Patient Investor' strategy. The company achieved a high score of 86%, indicating significant interest based on the model's criteria which favor predictable profitability and low debt. This rating is supported by LRCX passing crucial tests for earnings predictability, debt service, and free cash flow generation. Furthermore, the analysis positively rates the company's use of retained earnings and its active share repurchase program, signaling effective capital management and a commitment to shareholder returns. Despite these strengths, the report flags a notable weakness: Lam Research failed the criterion for Return on Total Capital, suggesting that while its return on equity is strong, its efficiency in generating returns from its entire capital base, including debt, warrants closer inspection.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment